Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$182.7B
1,730M shares
52-week range
$81.97 – $137.49
43% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
www.abbott.comNo one on the platform currently holds ABT.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,238,666 | $127.2M |
| Bridgewater Associatesas of 2026-03-31 | 117,051 | $12.0M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-15 | $0.6300 | 2026-08-17 |
| 2026-04-15 | $0.6300 | 2026-05-15 |
| 2026-01-15 | $0.6300 | 2026-02-13 |
| 2025-10-15 | $0.5900 | 2025-11-17 |
| 2025-07-15 | $0.5900 | 2025-08-15 |
| 2025-04-15 | $0.5900 | 2025-05-15 |
| 2025-01-15 | $0.5900 | 2025-02-14 |
| 2024-10-15 | $0.5500 | 2024-11-15 |
| 2024-07-15 | $0.5500 | 2024-08-15 |
| 2024-04-12 | $0.5500 | 2024-05-15 |
No one on the platform has traded ABT yet.
| 2024-01-11 | $0.5500 | 2024-02-15 |
| 2023-10-12 | $0.5100 | 2023-11-15 |
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$MYGN I’m a Buyer down 40% here… Yes the qtr and guide were BAD. But this co is still doing near $800MN in sales and will open at ~0.4x fwd EV/sales…rock bottom valuation for a strategic asset that could help expand the footprint in community oncology for a larger Dx player. $ABT is a clear acquirer. Expect this to recover to down ~20-25% and be an M&A target after. HODL. 😬🦾 $XLV $IHI $XBI
View on StockTwits ↗$ABT RSI was in the mid 70's & getting overextended into overbought territory after this beautiful run for us. Not a bad thing for us to experience a little healthy consolidation at these levels. $110+ is on the way for us shortly, & in the coming weeks 🥂
View on StockTwits ↗$ABT UBS Adjusts Price Target on Abbott Laboratories to $125 From $135, Maintains Buy Rating MT Newswires 10:17:22 AM ET, 07/28/2026
View on StockTwits ↗Wall St is expecting 1.42 EPS for $ABT Q3 [Reporting 10/21 BMO] http://www.estimize.com/intro/abt?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗$ABT potential cup and handle forming on 6 month chart. Need to rally to 118-120 (to fully form the cup) and then pullback to 112-115 (to fully form the handle) to confirm.
View on StockTwits ↗These 3 Companies Reported Record Results And Raised Guidance $ABT $TSM $JNJ https://talkmarkets.com/article/these-3-companies-reported-record-results-and-raised-guidance-1785307979
View on StockTwits ↗Global CGM Revenue: ~33.8% to 34% controlled by $DXCM, trailing $ABT FreeStyle Libre (~52%), with $MDT holding the remainder. $DXCM U.S. Market Share: ~74% of the domestic CGM sector, reflecting strong domestic adoption and insurance coverage.
View on StockTwits ↗$ABT key resistance levels: $106.50: big break throu this one already today. $109.23 is next, $111.96 is next, $125.75 is next.
View on StockTwits ↗$ABT can’t be greedy. Taking profits and rotating into $CRDO. One winner funds the next. 🚀
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $50.3B | +12.6% | $5.52 | $5.47–$5.55 | 19.1× | 17 |
| 2027 | $54.7B | +8.7% | $6.06 | $6.00–$6.18 | 17.4× | 17 |
| 2028 | $58.5B | +6.9% | $6.72 | $4.50–$8.06 | 15.7× | 10 |
| 2029 | $62.9B | +7.5% | $7.45 | $7.19–$7.56 | 14.2× | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-16 | $1.28 | $1.31 | +2.3% |
| 2026-04-16 | $1.14 | $1.15 | +0.9% |
| 2026-01-22 | $1.50 | $1.50 | +0.0% |
| 2025-10-15 | $1.30 | $1.30 | +0.0% |
| 2025-07-17 | $1.26 | $1.26 | +0.0% |
| 2025-04-16 | $1.07 | $1.09 | +1.9% |
| 2025-01-22 | $1.34 | $1.34 | +0.0% |
| 2024-10-16 | $1.20 |
| $1.21 |
| +0.8% |
| $109.7B |
| — |
| MRKMerck & Co., Inc. | $129.79 | -0.44% | $320.6B | — |
| NVONovo Nordisk A/S | $51.61 | +0.06% | $229.3B | — |
Source: Financial Modeling Prep · peers by sector/industry